Posted by Michael Wonder on 20 Sep 2020
Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union
18 September 2020 - Agreement signed today supports scale-up of manufacturing capabilities in several European countries.
Sanofi and GSK finalised and signed today an Advanced purchase agreement with the European Commission for the supply of up to 300 million doses of a COVID-19 vaccine, once the vaccine is approved. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.
This final agreement confirms the announcement made on July 31 by both companies and marks a key milestone in protecting European populations against COVID-19.
